Strategic committee

 

Dr. Avenard is CEO at Acticor Biotech and Board member or adviser for several companies through GABC, a Strategic Advisory Firm for Biotech and Pharma Industry. From 1997 to 2010, he served as COO of BioAlliance Pharma SA (BIO – NYSE-EURONEXT) since he co-founded the company. From 1990 to 1997, Dr. Avenard served as Medical Director of Development in the Cassenne Laboratories division of Hoechst Marion Roussel (Sanofi-Aventis Pharma).From 1976 to 1990, Dr. Avenard held various positions with the National Blood Transfusion Center in Paris, including Medical Director of Bio-Transfusion (LFB), providing human plasma products. He has also served as a physician in hemobiology and blood transfusion at the Blood Center of Pitié-Salpétrière Hospital in Paris. Dr. Avenard received his MD as well as degrees in hematology and hemobiology & blood transfusion from the School of Medicine at the University of Paris V. 

  • Jean-Pascal Conduzorgues Pharm.D.

As a pharmacist, Jean Pascal Conduzorgues has acquired a lot of experienced as a ‘qualified person’ (QP), a pharmaceutical leadership role required for medicine in Europe. He is the founder and director of CRID Pharma (a service provider which specialises in pharmaceutical development and the organisation of clinical trials) in Montpellier, which he has directed for 20 years. By merging CRID Pharma and Avogadro in 2011, he created the Amatsi group, a service company dedicated to medicine development,established in France and in the USA. Since 2013, Jean Pascal Conduworgues has ran Ibero, an advisory organisation, thanks to which he helps with pharmaceutical feedback for biotechnological companies.

Dr. Kaczorek holds a Ph.D. in oncology and microbiology. He has over thirty years experience in biotechnology, of which 13 in research and production of recombinant proteins and vaccines (Institut Pasteur, Harvard Medical School and then in the industry as Head of R&D at Pasteur Vaccins). Michel served as Cofounder and CSO at Protéine Performance (1992-1994), and founder & CEO at Synt:em SA (1995-2005). Both companies were based on technology transfer and were focused on the development of new drugs, from bench to clinical trials. During his career, Michel raised about €42 M  from French & European venture capitalists, is author of 9 patents and 50 peer reviewed publications. Since 2008, Michel acts as Director of Projects at “Pole de compétitivité” EuroBioMed (South of France), is Board member of two biotech companies (Splicos and Neurokin), Chairman of the Board of Kaphalios and CEO of Holding Incubatrice DM & Santé, Truffle Capital subsidiary, a private equity investment company based in Paris.

Les commentaires sont fermés.